Key facts
- This page summarizes Benjamin L. Palleiko's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Aug 2025, 17:29.
Benjamin L. Palleiko - 11 Aug 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- KALV
- Reported as of
- 11 Aug 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Aug 2025, 17:29:45 UTC
- Prior SEC filing
- 10 Jul 2025
- Next SEC filing
- 19 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Benjamin L. Palleiko
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Benjamin L. Palleiko filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 13 Aug 2025.
Change
- Previous filing in this sequence was filed on 10 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001366244
Primary reporting owner
Palleiko Benjamin L
- Relationship
- CHIEF EXECUTIVE OFFICER, Director
- Address
- C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE
- Signature
- /s/ Benjamin L. Palleiko
- Signature date
- 13 Aug 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALV
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +113,920
- Change %
- Price
- $0.000000
- Shares after
- 113,920
- Date
- 11 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 113,920
- Exercise price
- Footnotes
- F1, F2
KALV
transaction
Derivative
Employee Stock Option
Award
- Transaction value
- $0
- Shares
- +113,920
- Change %
- Price
- $0.000000
- Shares after
- 113,920
- Date
- 11 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 113,920
- Exercise price
- $12.51
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F2
1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 11, 2025, subject to continued service through each vesting date.
Footnote F3
The option vests over a 4 year period: 1/48th on September 11, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.